On Wednesday, October 11, 2023, we teamed up with Cyberport, HKMHDIA, and UMP Innov Centre to host the “Bright Ideas, Strong Barriers: A Patenting Masterclass” seminar, both in-person and online. Jennifer, our Managing Director, and Pauli, our Principal, took the stage and delivered presentations on the fundamentals of intellectual property (IP) and the challenges faced in MedTech/Healthcare innovation within the GBA and China.

We were privileged to have a distinguished panel of experts who generously shared their experiences and insights on the topic of “MedTech Innovations and Intellectual Property Protection.” Our esteemed panelists included Ronnie Li from UMP Healthcare Group as the moderator, Dr. Lydia Leung from HKMHDIA and Belun Technology, Mr. Justin Chan from Gense Technologies, Ms. Kim Chow from LinkAIQ, and our very own Managing Director, Ms. Jennifer Che.

At Eagle IP Limited, our mission is to assist both local and foreign inventors in safeguarding their creations and business endeavors. Through seminars like these, we aim to raise awareness about the importance of IP in the technology industry. We eagerly anticipate organizing more IP workshops and events for our community!






Our Past Events

Recommended Insights

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

28 February 2024
A Closer Look at the New Presumed Receipt Date Calculation Background China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how […]

How will Civil Cases Work under the Patent Linkage Provision in the New Chinese Patent Law?

20 November 2020
The Supreme People’s Court has just issued draft regulations for comment regarding how new Article 76 will work in conjunction with civil procedure law. The period to submit comments ends December 14, 2020, and the final version will come into force June 1, 2021, together with the new Chinese Patent Law. The Backdrop: New Chinese […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

28 May 2021
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]
Top crossarrow-right